Hermital, capsules 36000 units 20 pcs

Ermital contains standard highly active pancreatin derived from the pancreas of pigs in the form of micro tablets resistant to gastric juice.

A digestive enzyme, replenishes pancreatic enzyme deficiencies, has proteolytic, amylolytic and lipolytic action.

Included enzymes (lipase, alpha-amylase, trypsin, chymotrypsin) help to breakdown proteins into amino acids, fats into glycerol and fatty acids, starch into dextrins and monosaccharides, improves the functional state of the gastrointestinal tract and normalizes digestive processes.

Pharmacodynamics

The form of the drug ensures complete release of the gastric juice-resistant microtablets from the capsule in the stomach, followed by fine mixing of the microtablets with

intestinal contents and chyme and rapid release of enzymes from the microtablets in the duodenum at pH>5.

Pancreatic enzyme breakdown products are absorbed in the intestine either directly or after breakdown by intestinal enzymes.

Pharmacokinetics

The pancreatic enzymes contained in Hermital are not absorbed into the blood. The enzymes are inactivated and digested in the intestine as proteins by autolysis and proteolysis. Residual enzymatic activity can be determined in the stool.

Indications

Active ingredient

Composition

1 capsule of gastric juice-resistant microtablets contains:

Pancreatin from porcine pancreas 36,000 IU

Auxiliary substances:

Microcrystalline cellulose,

Crospovidone,

Silicon dioxide colloidal anhydrous,

Magnesium stearate.

The composition of the capsule cap:

Gelatin,

Red iron oxide (E172),

Iron oxide black (E172),

Titanium dioxide (E171),

Sodium lauryl sulfate.

Capsule body composition:

Gelatin,

Sodium lauryl sulfate.

The composition of the film coating of the microtablets:

Methacrylic acid and ethyl acrylate copolymer (1:1),

Triethylcitrate,

Talc,

Simethicone (20% emulsion, 23% on a dry weight basis),

The polishing agent is montan – glycolic wax.

How to take, the dosage

Interaction

If Ermital is taken, folic acid absorption may be decreased.

Ermital decreases iron absorption.

Per treatment with Ermital may decrease the effectiveness of hypoglycemic agents for oral administration – acarbose and myglitol.

Special Instructions

Contraindications

Side effects

Overdose

Symptoms: hyperuricosuria, hyperuricemia.

Treatment: drug withdrawal, symptomatic therapy.

Pregnancy use

The use of the drug during lactation (breastfeeding) is possible only when the estimated benefit of therapy for the mother outweighs the potential risk to the infant.

It is contraindicated in children.

Similarities